All News

With an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?

A new assessment shows year-over-year improvements on meeting DSCSA serialization requirements, which indicate the industry is making steady progress.

Gauging physician awareness of nucleic acid-based therapies.

Click the title above to open the Pharmaceutical Executive December 2019 issue in an interactive PDF format.

More than two years since the devastation inflicted by Hurricane Maria, Puerto Rico’s supply of medical products has remained largely uninterrupted, debunking common misconceptions at the time and maintaining the island’s standing as one of the most attractive life sciences manufacturing hubs.

A look at the systemic problems resulting from the overlap of MDRP and 340B.

A look at how to develop a generic drug and the resources FDA supplies to Abbreviated New Drug Application applications.

A review of the current use of real-world data and evidence in HTA and payer appraisals, its potential role in lifecycle management, and how the early dialogue provided by Integrated Scientific Advice engagement can be used as a key tool in the planning and generation of RWE.

Click the title above to open the Pharmaceutical Executive November 2019 issue in an interactive PDF format.

Click the title above to open Pharmaceutical Executive's 16th Annual Pipeline Report in an interactive PDF format.

Boasting a long and proud tradition in the life sciences, consistently ranked among the world’s most pioneering countries, Sweden’s biggest task will be to maintain such standards in an era where medical science is becoming ever more sophisticated and integrated with other disciplines.

reviews the two most salient changes in Academy of Managed Care Pharmacy's new Format for Formulary Submissions

Our quest to make sense of a complex future data ecosystem in pharma.

A look at highlights from the Digital Pharma East conference looking at technology and marketing innovation in pharma.

Leela Barham reacts to the Institute for Economic and Clinical Review's very first Unsupported Price Increase (UPI) report.